PTK2 and schwannoma: Although the ABPP identified at least ten potential candidates for crizotinib's activity, given the previous reports correlating NF2 deficiency to sensitivity of FAK1 inhibition [17, 18] we focused initially on FAK1 as the potential relevant crizotinib target in NF2-null schwannoma cells.